Abstract 4482
Background
Cancer and the adverse events of its treatment influence patients’ psychology and decrease their quality of life. The aim of this study was the investigation of the relationship between anxiety, depression and quality of life of ambulatory cancer patients undergoing chemotherapy.
Methods
This cross-sectional study was conducted in the one-day clinic of a large anticancer Hospital in Athens, Greece. Our convenience heterogeneous sample included 150 patients who received chemotherapy. Participants completed the Distress Thermometer and Problem List, the Hospital Anxiety and Depression Scale (HADS), the EORTC QLQ-C30 (version 3.0) for the assessment of Quality of life and the demographic and clinical characteristics questionnaire. Permission for the research was obtained by the ethical committee of the hospital. Data analysis was conducted by SPSS 22.0. The statistical significance level was set at p < 0.05.
Results
The mean age of the participants was 60.07±11.42 while 64% of the sample was female. The majority of patients reported worry (82.7%), fatigue (84.7%), fear (74.7%), nervousness, (51.3%) sadness (51.3%) and depression (34%). Female patients reported higher distress levels than male (p < 0,005). The participants’ educational level was found to correlate significantly with the cognitive functioning (p = 0.017) and financial impact (p = 0.026) subscales. Statistically significant positive correlations were found between HADS-anxiety and HADS-depression and symptom subscales of the EORTC QLQ-C30 questionnaire (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbances, appetite loss and financial impact). Statistically significant negative correlations were also found between HADS-anxiety and HADS-depression and the functional subscales of the EORTC QLQ-C30 questionnaire (physical, role, emotional, cognitive and social functioning).
Conclusions
Anxiety and depression have a negative influence on the quality of life of ambulatory cancer patients during chemotherapy. Nurses could play an important role in the recognition and management of these symptoms. Academics and nurse managers professionals need to enhance nurses’ knowledge and sensitivity and empower them to take an active role.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Program of Postgraduate Studies in "Neurological Disorders - Evidence Based Practice", Nursing Department, University of West Attica, Athens, Greece.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5071 - Expression of estrogen receptor and programmed cell death-ligand 1 can be complementary prognostic factors in HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Soohyeon Kwon
Session: Poster Display session 3
Resources:
Abstract
5306 - Real-world data of clinicopathologic characteristics of young oropharyngeal cancer patients.
Presenter: Maria Nieva
Session: Poster Display session 3
Resources:
Abstract
3407 - The clinical significance and biological mechanisms of miR-499a in high-tobacco exposed head and neck squamous cell carcinoma
Presenter: Shiqi Gong
Session: Poster Display session 3
Resources:
Abstract
3310 - Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic squamous cell carcinoma of the head and neck
Presenter: Rachel Galot
Session: Poster Display session 3
Resources:
Abstract
2362 - Blood-based testing of mutations in patients with Head and neck squamous cell carcinoma (HNSCC) using highly sensitive SafeSEQ technology
Presenter: Florentia Fostira
Session: Poster Display session 3
Resources:
Abstract
4533 - The head and neck Lung Immune Prognostic Index (HN-LIPI): a prognostic Score for Immune Checkpoint Inhibitors (ICI) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) patients.
Presenter: Ruth Gabriela Herrera Gomez
Session: Poster Display session 3
Resources:
Abstract
5262 - Immune-related adverse events (irAEs) and outcome in recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) patients (pts) treated by immune-checkpoints inhibitors (ICI)
Presenter: Neus Baste Rotllan
Session: Poster Display session 3
Resources:
Abstract
3725 - Intratumoral and peripheral exploratory biomarker analysis in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC) treated with RM-1929 photoimmunotherapy
Presenter: Jack Bui
Session: Poster Display session 3
Resources:
Abstract
2533 - A nomogram based prognostic score to predict overall survival (OS) in recurrent-metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with immune checkpoint inhibitors (ICI).
Presenter: Luay Mousa
Session: Poster Display session 3
Resources:
Abstract
2929 - Changes of the Commensal Microbiome during Treatment are Associated with Clinical Response in the Nasopharyngeal Carcinoma Patients
Presenter: Tingting Huang
Session: Poster Display session 3
Resources:
Abstract